Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Oncology

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Published in the New England Journal of Medicine after an ASCO presentation, regulators have authorised expanded access for daraxonrasib pending formal review.

3 ARTICLES

last mo.

Imfinzi With Enfortumab Vedotin Improves Survival in Phase III Bladder Cancer Trial

7 ARTICLES

last mo.

Pfizer Posts Higher Q1 Sales but Lower Profit, Raising Fresh Questions About Its Dividend

4 ARTICLES

last mo.

Pfizer Beats Q1 Forecasts as Newer Drugs Offset COVID Slide

6 ARTICLES

2mo ago

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

8 ARTICLES

2mo ago

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

19 ARTICLES

2mo ago

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

5 ARTICLES

8mo ago

Novartis Posts Q3 Sales Rise but Misses Views, Reaffirms 2025 Outlook

11 ARTICLES

9mo ago

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

6 ARTICLES

11mo ago

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss